MX2021005686A - Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. - Google Patents

Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.

Info

Publication number
MX2021005686A
MX2021005686A MX2021005686A MX2021005686A MX2021005686A MX 2021005686 A MX2021005686 A MX 2021005686A MX 2021005686 A MX2021005686 A MX 2021005686A MX 2021005686 A MX2021005686 A MX 2021005686A MX 2021005686 A MX2021005686 A MX 2021005686A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
ceacam6
pharmaceutical combination
antibodies
Prior art date
Application number
MX2021005686A
Other languages
English (en)
Inventor
Mark Trautwein
Jörg Willuda
Rienk Offringa
Philipp Beckhove
Hans-Henning Böhm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2021005686A publication Critical patent/MX2021005686A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente invención se refiere a combinaciones de al menos dos componentes, el componente A y el componente B, siendo el componente A un anticuerpo anti-CEACAM6 y siendo el componente B un anticuerpo anti-PD-1, con preferencia, nivolumab o pembrolizumab, o un anticuerpo anti-PD-L1, con preferencia, atezolizumab, avelumab o durvalumab.
MX2021005686A 2018-11-14 2019-11-07 Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. MX2021005686A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18206206 2018-11-14
PCT/EP2019/080520 WO2020099230A1 (en) 2018-11-14 2019-11-07 Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021005686A true MX2021005686A (es) 2021-07-07

Family

ID=64572076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005686A MX2021005686A (es) 2018-11-14 2019-11-07 Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20220010017A1 (es)
EP (1) EP3880705A1 (es)
JP (1) JP2022513036A (es)
KR (1) KR20210091152A (es)
CN (1) CN112996814A (es)
AU (1) AU2019379261A1 (es)
BR (1) BR112021007448A2 (es)
CA (1) CA3119563A1 (es)
IL (1) IL283064A (es)
MX (1) MX2021005686A (es)
SG (1) SG11202105078XA (es)
WO (1) WO2020099230A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021007968A2 (pt) * 2018-12-19 2021-09-08 Bayer Aktiengesellschaft Combinação farmacêutica de anticorpos anti-ceacam6 e tim3
AU2022340907A1 (en) 2021-09-02 2024-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
AU2012290121B2 (en) * 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN107106687A (zh) * 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
SG10201810615VA (en) * 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
CN107743495B (zh) * 2015-03-23 2021-05-14 拜耳制药股份公司 抗ceacam6抗体及其用途
EP3560957A4 (en) * 2016-11-14 2020-10-21 Dinona ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE

Also Published As

Publication number Publication date
EP3880705A1 (en) 2021-09-22
US20220010017A1 (en) 2022-01-13
BR112021007448A2 (pt) 2021-10-26
KR20210091152A (ko) 2021-07-21
AU2019379261A8 (en) 2021-08-05
JP2022513036A (ja) 2022-02-07
WO2020099230A1 (en) 2020-05-22
AU2019379261A1 (en) 2021-05-27
CN112996814A (zh) 2021-06-18
CA3119563A1 (en) 2020-05-22
SG11202105078XA (en) 2021-06-29
IL283064A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
MX2016011155A (es) Anticuerpo que une erbb-2 y erbb-3.
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
MX2018012651A (es) Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4).
MX2017015039A (es) Combinaciones de inmunoconjugado anti-cd37 y anticuerpo anti-cd20.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
MX2019000727A (es) Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
MX2020008122A (es) Anticuerpos anti-pd-1.
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX2019010797A (es) Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2020002406A (es) Anticuerpo anti-epha4.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2019013753A (es) Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.